Gloperba Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are reporting difficulty filling Gloperba prescriptions, they're not alone. As the only FDA-approved oral liquid formulation of Colchicine, Gloperba occupies a unique niche in gout prophylaxis — and that uniqueness is part of the problem. This guide provides prescribers with a current overview of the Gloperba supply situation, clinical alternatives, and tools to help patients access their medication.

Understanding the Supply Landscape

Gloperba (Colchicine oral solution, 0.6 mg/5 mL) was FDA-approved in 2018. It is manufactured by a single company, and no generic oral solution equivalent exists. This creates a fragile supply chain where any manufacturing disruption has an outsized impact on national availability.

Key factors driving the current supply challenges:

• Single-source production: No alternative manufacturers for the liquid formulation
• High acquisition cost: Wholesale costs of $500–$700+ per month discourage pharmacy stocking
• Limited formulary coverage: Many payers require prior authorization or step therapy through Colchicine tablets first
• Low prescription volume: The small patient population reduces distributor priority
• No FDA-listed shortage: Localized availability issues may not trigger formal shortage designation

Clinical Context: Who Needs Gloperba Specifically?

For most patients on Colchicine prophylaxis, the tablet or capsule formulation is clinically equivalent. However, Gloperba fills a critical need for specific patient populations:

• Dysphagia patients: Those with swallowing difficulties due to neurological conditions, stroke, head and neck cancers, or age-related decline
• Feeding tube patients: Patients receiving nutrition and medications via nasogastric, PEG, or other enteral tubes
• Pediatric or geriatric patients: Those who cannot reliably swallow solid oral dosage forms
• Medication adherence challenges: Some patients demonstrate better adherence with liquid formulations

When a patient specifically requires liquid Colchicine and Gloperba is unavailable, the clinical decision-making becomes more nuanced.

Prescribing Alternatives

Option 1: Generic Colchicine Tablets

For patients who can transition to solid oral forms, generic Colchicine tablets (0.6 mg) offer equivalent efficacy at a fraction of the cost. This is the most straightforward substitution for patients without swallowing limitations.

Option 2: Brand-Name Colchicine (Colcrys, Mitigare)

Colcrys (tablets) and Mitigare (capsules) are brand-name alternatives. They may offer improved insurance coverage compared to Gloperba in some formularies. Dosing is equivalent at 0.6 mg.

Option 3: Compounded Liquid Colchicine

For patients who require a liquid formulation, compounding represents the most viable alternative. Key considerations:

• The prescriber must write the prescription specifically for a compounding pharmacy
• Choose a pharmacy with PCAB accreditation or state board of pharmacy oversight
• Compounded formulations are not FDA-approved; stability and bioavailability may differ
• Insurance coverage for compounded medications varies significantly
• Document the medical necessity for the liquid formulation in the patient's chart

Option 4: Alternative Prophylactic Agents

When Colchicine in any form is unavailable or contraindicated, consider:

• Low-dose NSAIDs: Naproxen 250 mg BID or Indomethacin 25 mg BID during initiation of urate-lowering therapy. Assess renal function, cardiovascular risk, and GI history before prescribing.
• Low-dose Prednisone: 5–10 mg daily may be used as prophylaxis in patients who cannot take Colchicine or NSAIDs. Monitor for adverse metabolic effects with prolonged use.
• IL-1 inhibitors: Anakinra or Canakinumab may be considered in refractory cases, though these are not standard first-line prophylaxis and carry significant cost.

Drug Interaction Considerations When Switching

If transitioning patients from Gloperba to alternative Colchicine formulations, the drug interaction profile remains the same, as the active ingredient is identical. Key interactions to monitor:

• Strong CYP3A4 inhibitors (Clarithromycin, Ketoconazole, HIV protease inhibitors): Colchicine dose reduction required; concomitant use contraindicated in renal/hepatic impairment
• Moderate CYP3A4 inhibitors (Erythromycin, Diltiazem, Verapamil, Fluconazole): Dose adjustment may be needed
• P-glycoprotein inhibitors (Cyclosporine, Ranolazine): Increased Colchicine levels; dose reduction required
• Statins: Increased risk of myopathy and rhabdomyolysis with concurrent use

For a patient-facing overview of interactions, see Gloperba Drug Interactions: What to Avoid.

Tools to Help Your Patients

MedFinder for Providers

Direct your patients to MedFinder to search for Gloperba availability by zip code. For provider-specific tools and resources, visit medfinder.com/providers.

Prior Authorization Support

If your patient's insurance requires prior authorization for Gloperba, document the clinical rationale clearly:

• Diagnosis of gout with indication for Colchicine prophylaxis
• Specific medical reason the patient requires liquid formulation (e.g., dysphagia, feeding tube)
• Previous trial of or contraindication to solid oral Colchicine, if applicable

Patient Assistance Programs

The manufacturer may offer copay assistance or patient assistance programs for qualifying patients. Third-party resources include NeedyMeds, RxAssist, and discount card programs like GoodRx and SingleCare. For patient-facing cost-saving information, refer patients to How to Save Money on Gloperba in 2026.

Documentation Best Practices

When navigating Gloperba access issues, thorough documentation supports both clinical care and insurance appeals:

• Document the medical necessity for liquid Colchicine specifically
• Note any failed attempts to fill the prescription and pharmacy responses
• Record conversations with insurance companies regarding prior authorization
• If switching to an alternative, document the reason for the change and counseling provided

Staying Informed

Monitor these resources for updates on Colchicine supply:

• FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages
• ASHP Drug Shortage Resource Center: Provides clinical guidance during shortages
• MedFinder: medfinder.com/providers for real-time availability data

For a practical guide on helping patients find Gloperba, see How to Help Your Patients Find Gloperba in Stock. For the patient-facing shortage update, see Gloperba Shortage Update: What Patients Need to Know in 2026.

The Bottom Line

Gloperba's single-source status and high cost make it vulnerable to supply disruptions. For most patients, generic Colchicine tablets are a clinically equivalent and readily available alternative. For patients who specifically need a liquid formulation, compounding is the most practical fallback. Proactive communication with patients, thorough documentation, and awareness of available tools like MedFinder for Providers can help you navigate these challenges effectively.